7th CNS Drug Delivery Summit

Despite milestones such as Roche's Trontinemab Brainshuttle™ achieving robust amyloid clearance, challenges remain in reaching targeted brain regions, improving predictive modelling, ensuring efficacy and penetrance, and developing safer, targeted delivery approaches.
 
 
Join 100+ industry experts spanning neuroscientists, chemists, device engineers, conjugation scientists, DMPK experts, delivery specialists, and more at the 7th CNS Drug Delivery Summit to collaborate, network, and learn cutting-edge strategies that are tackling the unique challenges in gaining access to the brain.
 
 
Gain actionable insights from case studies, presentations, and deep-dive discussions on CNS drug delivery strategies covering systemic and local delivery, blood-brain barrier targeting, RMT modulation, and emerging modalities from Biogen, Sanofi, Merck, UCB, Eli Lilly, Alnylam, Voyager, and more, to advance brain access and accelerate CNS therapy development.
 
 
Speakers: Ajit D'Souza, Executive Director Drug Delivery and Devices DDCS, Eli Lilly and Co, Anil Tarachandani, Vice President and Head of Translational Medicine, Verge Genomics, Anthony Coston, Principal Engineer, Biogen, Chris Kadamus, Executive Director of Engineering, Eli Lilly and Co, Eden Fucci, Senior Vice President Head of Technical Operations, Passage Bio, Ethan Lippmann, Associate Professor, Department of Chemical and Biomolecular Engineering, University of Vanderbilt, Evgenii Boriushkin, Chief Executive Officer, Tropocan, Gi-Hoon Nam, Chief Executive Officer, Shiftbio, Haiming Wu, Head of New Device Technology Research and Innovation, Sanofi, Iwona Ziomkiewicz, Drug Discovery Manager, Parkinsons, Jamie Tsung, Director DP Formulation and CMC, Alnylam Pharmaceuticals, Jingjing Gao, Assistant Professor of Biomedical Engineering, University of Massachusetts Amherst, Lisa Shafer, Vice President - Product Development and Reg Chemistry, Manufacturing, Controls, Medical Devices and Packaging, Biogen, Mathias Schmidt, Chief Executive Officer, ArmaGen, Natasha Sheybani, Research Director of UVA Focused Ultrasound Cancer Immunotherapy Center, University of Virginia, Parnian Lak, Chief Executive Officer and Co- Founder, Olfera, Peter Horanyi, Senior Principal Scientist, UCB, Rajeev Sivasankaran, Senior Vice President and Head of Neuroscience, Voyager Therapeutics, Sandeep Kunwar, Chief Executive Officer and Founder, Precision NeuroMed, Sandra Vergo, Research Fellow (Senior Specialist), Lundbeck, Seth Forster, Associate Principal Scientist, Discovery Pharmaceutical Sciences, Merck, Thomas Joudinaud, Chief Executive Officer and Co-Founder, Ceres Brain Therapeutics, Toey Nivitchanyong, Senior Staff Scientist, Alector, Willard Costain, Senior Research Officer, Government of Canada